Literature DB >> 8012774

Abnormalities in p53 and DNA content in transitional cell carcinoma of the bladder.

K Mellon1, S Wilkinson, J Vickers, M C Robinson, B K Shenton, D E Neal.   

Abstract

OBJECTIVE: To determine if transitional cell tumours of the bladder which contain mutations in the p53 gene have alterations in their DNA content.
MATERIALS AND METHODS: In 33 transitional cell tumours of the bladder, DNA content was determined by flow cytometry and compared with expression of mutant p53 as assessed by immuno-histochemistry.
RESULTS: Abnormal DNA content was associated with increased staining for p53 (P < 0.05), high tumour stage (P < 0.001) and increased histological grade (P < 0.01). Although positive staining for p53 was frequently associated with abnormal DNA content, a significant number of non-diploid tumours stained negatively for mutant p53.
CONCLUSION: These data demonstrate that increased staining for p53 is associated with abnormalities in DNA content suggesting that mutation of the p53 gene is associated with an increased rate of chromosomal abnormalities and an increased rate of cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8012774     DOI: 10.1111/j.1464-410x.1994.tb07637.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  3 in total

1.  Correlation of nuclear p53 over-expression with clinical and histopathological features of transitional cell bladder cancer.

Authors:  Z Sinik; T Alkibay; O Ataoğlu; G Akyol; H Tokuçoğlu; I Bozkirli
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

2.  Accumulation of p53 protein in inverted transitional cell papilloma of the urinary bladder.

Authors:  K W Chan; K Y Lam; G Srivastava
Journal:  Clin Mol Pathol       Date:  1996-02

3.  Detection of P53 tumor-suppressor-gene protein in bladder tumors and prostate cancer: possible clinical implications.

Authors:  M A Kuczyk; J Serth; C Hervatin; H Arndt; L Derendorf; W F Thon; U Jonas
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.